Abeona Therapeutics Inc.

ABEO

$5.53

Updated: 24/09/2026, 05:36:51

Market Cap

$315.18M

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for ABEO

Company Profile

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

USD

NASDAQ

CEO: Vishwas Seshadri

Employees: 226

https://www.abeonatherapeutics.com

Asset Summaries

Latest generated summaries for ABEO

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for ABEO.

Share price: $5.53
Market cap: $315.18M
Exchange: NASDAQ
Currency: USD
CEO: Vishwas Seshadri
Employees: 226
IPO date: 19/09/1980
Beta: 1.324
Last dividend: $0.00
Day range: $5.52 – $5.90
52-week range: $4.00 – $7.65
1-day performance: -4.98%
1-year performance: 38.25%
Current drawdown (1Y): -27.71%
CIK: 0000318306
CUSIP: 00289Y206
ISIN: US00289Y2063
Created: 07/12/2025, 01:53:09
Last update: 24/09/2026, 05:36:51

Track Abeona Therapeutics Inc. with an AI analyst

See which prediction-market events move ABEO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to ABEO from your Railway `news_articles` table.

Abeona Therapeutics (NASDAQ: ABEO) Price Target Lowered Amid Operational Challenges

Market Data • Market Data • 14/08/2026, 20:11:19

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

GlobeNewsWire • STOCK • 26/05/2026, 10:30:00

Abeona Therapeutics Inc. (NASDAQ: ABEO) Sees Insider Share Sale Amidst ZEVASKYN Commercial Momentum

Market Data • Market Data • 15/05/2026, 23:11:04

Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 13/05/2026, 17:50:47

Abeona Therapeutics Q1 Earnings Call Highlights

MarketBeat • STOCK • 13/05/2026, 12:08:38

Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

GlobeNewsWire • STOCK • 13/05/2026, 09:30:00

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

GlobeNewsWire • STOCK • 02/04/2026, 10:30:00

Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB

Seeking Alpha • STOCK • 19/03/2026, 14:18:25

Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

GlobeNewsWire • STOCK • 09/03/2026, 08:30:00